Cassava Sciences reported $112.38M in Cash and Equivalent for its fiscal quarter ending in June of 2025.




Cash And Equivalent Change Date
Abbott USD 6.95B 419M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Cassava Sciences USD 112.38M 16.19M Jun/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Geron USD 79.6M 6.01M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Merck USD 8.01B 622M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024